Lercanidipino Cinfa

Lercanidipine, the active ingredient in Lercanidipino Cinfa, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle.

GNH USA supplies Lercanidipino Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU quality standards and is manufactured under GMP conditions. It is available for export to regulated markets following appropriate regulatory approvals.

Lercanidipine acts on the vascular smooth‑muscle calcium channels to control blood pressure in hypertensive disease. - Hypertension: reduction of elevated blood pressure in adult patients.

Lercanidipine may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heart beating.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may compromise airway. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Monitor blood pressure: ensure therapeutic targets are achieved without excessive lowering. - Assess hepatic function: consider baseline liver tests and periodic monitoring. - Use caution in the elderly: increased susceptibility to hypotension and dizziness. - Avoid strong CYP3A4 inhibitors: concomitant use may raise plasma concentrations. - Pregnancy and lactation: safety has not been established; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug exposure leading to excessive blood pressure reduction.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (ACE inhibitors, diuretics): additive blood‑pressure‑lowering effect. - Beta‑blockers: may enhance bradycardia or heart‑rate changes. - NSAIDs: may attenuate antihypertensive efficacy. - Simvastatin: increased risk of statin‑related muscle toxicity.